HHS announces Affordable Care Act mental health services funding

$50 million from the health care law will expand mental health and substance use disorder services in approximately 200 Community Health Centers nationwide

The U.S. Department of Health and Human Services (HHS) today announced that it plans to issue a $50 million funding opportunity announcement to help Community Health Centers establish or expand behavioral health services for people living with mental illness, and drug and alcohol problems.  Community Health Centers will be able to use these new funds, made available through the Affordable Care Act, for efforts such as hiring new mental health and substance use disorder professionals, adding mental health and substance use disorder services, and employing team-based models of care. 

“Most behavioral health conditions are treatable, yet too many Americans are not able to get needed treatment,” said Health Resources and Services Administration (HRSA) Administrator Mary K. Wakefield, Ph.D., R.N.  “These new Affordable Care Act funds will expand the capacity of our network of community health centers to respond to the mental health needs in their communities.”

Read More 

Pharmacists Report Soaring Generic Drug Purchasing Prices

Alexandria, Va. Dec. 9, 2013 - Pharmacy acquisition costs for scores of generic drugs have spiked by as much as 600%, 1,000% or more in 2013, a problem that is harming patient care and pharmacists, according to a survey of more than 1,000 community pharmacists conducted by the National Community Pharmacists Association (NCPA).

"Once generic drugs become available, lower costs typically follow and community pharmacists are leading the way to maximize the savings for patients and health plans from the proper use of generics," said B. Douglas Hoey, RPh, MBA. "However, pharmacy acquisition costs for more and more generic drugs are rising in rapid, breathtaking fashion. This is having a negative impact on a number of patients, particularly Medicare beneficiaries. Meanwhile, reimbursement from pharmacy benefit managers (PBMs) is not keeping up, leaving pharmacists out in the cold and putting patient access to pharmacist care on unsustainable footing."

Secretary Sebelius announces new HHS regional director

HHS Secretary Kathleen Sebelius announced today that Kim Gillan will be appointed Region VIII Director of the U.S. Department of Health and Human Services.

"I am excited to welcome Kim Gillan to the team at HHS,” said Secretary Sebelius. “Kim is a long-time public servant, who brings with her a wealth of experience from her time in both the Montana House of Representatives and the Montana Senate, as well as at Montana State University.  She has been actively engaged on a number of health related policy initiatives and has worked at the regional level to improve the health and well-being of all Montanans.  Kim will join our team of regional directors who work tirelessly with state, local and tribal officials and external stakeholders on a wide range of health and social service issues, particularly as we continue to implement the Affordable Care Act. We look forward to adding Kim’s many strengths to the HHS team.”

Fight the Fakes - Fake Medicines Put Patients and the Public at Risk

Counterfeit and substandard medicines have reached global health crisis proportions, and present a real danger to all of us.  In a concerted effort to help protect people from fake medicines, the United States Pharmacopeial Convention (USP) is joining other global health organizations, including two USP Member organizations (International Council of Nurses and International Federation of Pharmaceutical Manufacturers and Associations), in a campaign to raise awareness and mobilize strategic partners to address this growing problem. 

New Resource from CDC on Pharmacists in Team Based Care

The Center for Disease Control and Prevention (CDC) recently released a set of tools to inform health care providers, decision-makers, insurers, and pharmacists about the role of pharmacists in team based care. These documents, called translational tools because they translate the research about pharmacists’ patient care services into a guide for policy change, include strategies and case examples of how pharmacists and other health care providers can better serve patients through collaborative practice agreements and collaborative drug therapy management. The translational tools were developed with content from the APhA Foundation’s consortium on collaborative practice agreements and pharmacists’ patient care services held in January of 2012. More information about these resources can be found in the APhA Foundation’s press release and on the CDC’s website.

FDA Releases Compounding Guidances

Agency moving quickly, aggressively to implement DQSA

FDA yesterday issued three guidances in draft form that implement the newly signed Drug Quality and Safety Act (DQSA). FDA is taking an aggressive stance in regulating the industry and traditional pharmacies, including a surprising reliance on USP Chapters <795> and <797> in the pharmacy compounding guidance that has potentially far-reaching impact on practice.

“The pharmacy compounding guidance revokes the 1998 and 2002 current good manufacturing practices (cGMPs) from FDA that regulated traditional pharmacy compounding and replaces them with this document,” said Lee Rosebush, PharmD, JD, MBA, MS, Counsel at the Baker-Hostetler law firm in Washington, DC, in describing the impact of these regulations if they are adopted unchanged. “By doing so, FDA has provided 10 conditions that must be met before a compounded drug meets the exemption under Section 503A [of the Federal Food, Drug, and Cosmetic Act]. One condition references both USP chapter <795> and USP chapter <797>. These are the chapters for both nonsterile and sterile pharmacy compounding. In other words, all compounding—including mixing powder antibiotics with water—must be done under USP standards.”

Read More